Hostname: page-component-78c5997874-fbnjt Total loading time: 0 Render date: 2024-11-02T18:46:56.327Z Has data issue: false hasContentIssue false
  • English
  • Français

MEK and RAF inhibitors for BRAF-mutated cancers

Published online by Cambridge University Press:  12 October 2012

Sarah Belden  and
Keith T. Flaherty
Sarah Belden
Affiliation:
Massachusetts General Hospital Cancer Center, Boston, MA, USA University of New England College of Osteopathic Medicine, Biddeford, ME, USA
Keith T. Flaherty*
Affiliation:
Massachusetts General Hospital Cancer Center, Boston, MA, USA
*
*Corresponding author: Keith T. Flaherty, Massachusetts General Hospital Cancer Center, 55 Fruit Street, Yawkey 9E, Boston, MA 02114, USA. E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

The mitogen-activated protein kinase (MAPK) pathway has been implicated in the pathophysiology of many cancers. Under normal physiologic conditions, the RAS–RAF–mitogen-activated protein kinase kinase (MEK)–mitogen-activated protein kinase (ERK) signalling cascade interaction is initiated by ligation of a receptor-linked tyrosine kinase by its cognate growth factor. It has been demonstrated in many systems that aberrant autocrine or paracrine stimulation of growth factor receptors is pathogenic in large part because of MAPK activation. As one of the key downstream effector pathways of mutated RAS (KRAS, NRAS and HRAS), pharmacologic inhibition of components of the MAPK pathway has been pursued as a means to indirectly inhibit RAS, which remains a technical challenge for direct pharmacologic inhibition. RAF and MEK are the two non-membrane-bound, serine–threonine and tyrosine–threonine kinases, within the pathway that have been most extensively explored as drug targets. The discovery of activating BRAF mutations in cancer clarified which cancer types and subsets of certain cancers are most dependent on activation of the MAPK pathway for growth and survival. Now, with the successful translation of selective BRAF and MEK inhibitors into validated therapies for BRAF mutant melanoma, the field seeks to resolve the role for these agents in cancers harbouring RAS mutations or those driven by aberrant growth factor receptor activation.

Type
Review Article
Information
Expert Reviews in Molecular Medicine , Volume 14 , March 2012 , e17
Copyright
Copyright © Cambridge University Press 2012

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

References

1Davies, H. et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417, 949-954CrossRefGoogle ScholarPubMed
2Long, G.V. et al. (2011) Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. Journal of Clinical Oncology 29, 1239-1246CrossRefGoogle ScholarPubMed
3Jakob, J.A. et al. (2012) NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 118, 4014-4023Google Scholar
4Tiacci, E. et al. (2011) BRAF mutations in hairy-cell leukemia. New England Journal of Medicine 364, 2305-2315Google Scholar
5Smalley, K.S. et al. (2009) CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. Oncogene 28, 85-94CrossRefGoogle ScholarPubMed
6Mielgo, A. et al. (2011) A MEK-independent role for CRAF in mitosis and tumor progression. Nature Medicine 17, 1641-1645CrossRefGoogle ScholarPubMed
7Roring, M. et al. (2012) Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling. EMBO Journal 31, 2629-2647Google Scholar
8Dumaz, N. et al. (2006) In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Research 66, 9483-9491CrossRefGoogle ScholarPubMed
9Wellbrock, C. et al. (2008) Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF. PLoS One 3, e2734Google Scholar
10Poulikakos, P.I. et al. (2010) RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464, 427-430Google Scholar
11Pratilas, C.A. et al. (2009) (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proceedings of the National Academy of Sciences of the United States of America 106, 4519-4524Google Scholar
12Heidorn, S.J. et al. (2010) Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140, 209-221CrossRefGoogle ScholarPubMed
13Gilmartin, A.G. et al. (2012) GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clinical Cancer Research 17, 989-1000CrossRefGoogle Scholar
14Schad, K. et al. (2010) Mitogen-activated protein/extracellular signal-regulated kinase kinase inhibition results in biphasic alteration of epidermal homeostasis with keratinocytic apoptosis and pigmentation disorders. Clinical Cancer Research 16, 1058-1064Google Scholar
15Flaherty, K.T. et al. (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. New England Journal of Medicine 363, 809-819CrossRefGoogle ScholarPubMed
16Sharfman, W.H. et al. (2011) Results from the first-in-human phase I study of the oral RAF inhibitor RAF265 administered daily to patients with advanced cutaneous melanoma. Journal of Clinical Oncology 29, 8508CrossRefGoogle Scholar
17Eisen, T. et al. (2006) Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. British Journal of Cancer 95, 581-586CrossRefGoogle ScholarPubMed
18Schwartz, G.K. et al. (2009) A phase I study of XL281, a selective oral RAF kinase inhibitor, in patients with advanced solid tumors. Journal of Clinical Oncology 27, 3513CrossRefGoogle Scholar
19Falchook, G.S. et al. (2012) Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 379, 1893-1901Google Scholar
20Karasarides, M. et al. (2004) B-RAF is a therapeutic target in melanoma. Oncogene 23, 6292-6298Google Scholar
21Whittaker, S. et al. (2010) Gatekeeper mutations mediate resistance to BRAF-targeted therapies. Science Translational Medicine 2, 35ra41Google Scholar
22Wilhelm, S.M. et al. (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Research 64, 7099-7109Google Scholar
23Wellbrock, C. et al. (2004) V599EB-RAF is an oncogene in melanocytes. Cancer Research 64, 2338-2342Google Scholar
24Bollag, G. et al. (2010) Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467, 596-599Google Scholar
25Greger, J. et al. (2012) Combinations of BRAF, MEK, and PI3 K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Molecular Cancer Therapeutics 11, 909-920Google Scholar
26Sosman, J.A. et al. (2012) Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. New England Journal of Medicine 366, 707-714Google Scholar
27Chapman, P.B. et al. (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. New England Journal of Medicine 364, 2507-2516CrossRefGoogle ScholarPubMed
28Ott, P.A. et al. (2010) A phase II trial of sorafenib in metastatic melanoma with tissue correlates. PLoS One 5, e15588Google ScholarPubMed
29Kim, K. et al. (2011) Pattern and outcome of disease progression in phase I study of vemurafenib in patients with metastatic melanoma (MM). Journal of Clinical Oncology 29, 8519CrossRefGoogle Scholar
30Lynch, T.J. et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New England Journal of Medicine 350, 2129-2139Google Scholar
31Kwak, E.L. et al. (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. New England Journal of Medicine 363, 1693-1703Google Scholar
32Kopetz, S. et al. (2010) PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. Journal of Clinical Oncology 28: 15s (suppl; abstr 3534)CrossRefGoogle Scholar
33Corcoran, R.B. et al. BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Sci Signal 3, ra84Google Scholar
34Prahallad, A. et al. (2012) Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483, 100-103Google Scholar
35Corcoran, R.B. et al. (2012) EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discovery 2, 227-235CrossRefGoogle ScholarPubMed
36McArthur, G.A. et al. (2011) Molecular analyses from a phase I trial of vemurafenib to study mechanism of action and resistance in repeated biopsies from BRAF mutation-positive metastatic melanoma patients. Journal of Clinical Oncology 29, 8502Google Scholar
37Paraiso, K.H. et al. (2010) Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. British Journal of Cancer 102, 1724-1730Google Scholar
38Nazarian, R. et al. (2010) Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468, 973-977Google Scholar
39Johannessen, C.M. et al. (2010) COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468, 968-972Google Scholar
40Poulikakos, P.I. et al. (2011) RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480, 387-390Google Scholar
41Shi, H. et al. (2012) Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nature Communications 3, 724CrossRefGoogle ScholarPubMed
42Montagut, C. et al. (2008) Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Research 68, 4853-4861Google Scholar
43Villanueva, J. et al. (2010) Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3 K. Cancer Cell 18, 683-695Google Scholar
44Shi, H. et al. (2011) Combinatorial treatments that overcome PDGFRbeta-driven resistance of melanoma cells to V600EB-RAF inhibition. Cancer Research 71, 5067-5074Google Scholar
45Paraiso, K.H. et al. (2011) PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Research 71, 2750-2760Google Scholar
46Xing, F. et al. (2012) Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF. Oncogene 31, 446-457Google Scholar
47Jia, S. et al. (2008) Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature 454, 776-779Google Scholar
48Engelman, J.A. et al. (2010) Targeting PI3 K signalling in cancer: opportunities, challenges and limitations. Nature Reviews Cancer 9, 550-562Google Scholar
49Infante, J.R.F. et al. (2010) Safety and efficacy results from the first-in-human study of the oral MEK 1/2 inhibitor GSK1120212. Journal of Clinical Oncology 28:15s, (suppl; abstr 2503)CrossRefGoogle Scholar
50Kim, K.B.L. et al. (2011) A Phase II study of the MEK1/MEK2 inhibitor GSK1120212 in metastatic BRAF-V600E or K mutant cutaneous melanoma patients previously treated with or without a BRAF inhibitor. Pigment Cell & Melanoma Research (PCMR) Volume 24, Issue 5, October 2011, Pages: 992Google Scholar
51Flaherty, K.I. et al. (2011) Phase I/II study of BRAFi GSK2118436 + MEKi GSK1120212 in patients with BRAF mutant metastatic melanoma who progressed on a prior BRAFi. Pigment Cell & Melanoma Research (PCMR) Volume 24, Issue 5, October 2011, Pages: 992Google Scholar
52Infante, J.R. et al. (2011) Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436). Journal of Clinical Oncology 29, 8503Google Scholar
53Guldberg, P. et al. (1997) Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Research 57, 3660-3663Google Scholar
54McArthur, G.A. et al. (2012) Clinical significance of genomic alterations of the CDK4-pathway and sensitivity to the CDK4 inhibitor PD 0332991 in melanoma. Journal of Clinical Oncology 30, (suppl; abstr 8520)CrossRefGoogle Scholar
55Smalley, K.S. et al. (2008) Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Molecular Cancer Therapy 7, 2876-2883Google Scholar
56Anders, L.K. et al. (2011) A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells. Cancer Cell 20, 620-634Google Scholar
57Boni, A. et al. (2010) Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Research 70, 5213-5219Google Scholar
58Wilmott, J.S. et al. (2012) Selective BRAF inhibitors induce marked T cell infiltration into human metastatic melanoma. Clinical Cancer Research 18, 1386-1394Google Scholar
59Roesch, A. et al. (2010) A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 141, 583-594Google Scholar
60Frank, N.Y. et al. (2005) ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Research 65, 4320-4333CrossRefGoogle ScholarPubMed
61White, R.M. et al. (2011) DHODH modulates transcriptional elongation in the neural crest and melanoma. Nature 471, 518-522Google Scholar

Further reading

http://mmdm.cancercommons.org/ml/index.php/A_Melanoma_Molecular_Disease_ModelGoogle Scholar